These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17990241)

  • 1. Similar challenges with retention in care issues.
    Krentz HB; Siemieniuk RA; Gill MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527. PubMed ID: 17990241
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?
    Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ
    Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234
    [No Abstract]   [Full Text] [Related]  

  • 3. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges.
    Katabira ET; Oelrichs RB
    AIDS; 2007 Jul; 21 Suppl 4():S5-10. PubMed ID: 17620753
    [No Abstract]   [Full Text] [Related]  

  • 4. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult.
    Flanigan TP; Mitty JA
    Clin Infect Dis; 2006 Jun; 42(11):1636-8. PubMed ID: 16652322
    [No Abstract]   [Full Text] [Related]  

  • 5. Adherence to antiretroviral therapy in pregnancy.
    Kingston MA; Letham CJ; McQuillan O
    Int J STD AIDS; 2007 Nov; 18(11):787-9. PubMed ID: 18005515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of 'universal access'.
    Harries AD; Makombe SD; Schouten EJ; Ben-Smith A; Jahn A
    Trans R Soc Trop Med Hyg; 2008 Apr; 102(4):310-1. PubMed ID: 18316103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge of and adherence to antiretroviral therapy.
    Parienti JJ
    Clin Infect Dis; 2003 Sep; 37(6):861-2; author reply 862-3. PubMed ID: 12955656
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient self-report as a marker of adherence to antiretroviral therapy.
    Ho CF; Fong OW; Wong KH
    Clin Infect Dis; 2002 Jun; 34(11):1534-5. PubMed ID: 12015702
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary care issues for HIV-infected patients.
    Cohen DE; Mayer KH
    Infect Dis Clin North Am; 2007 Mar; 21(1):49-70, viii. PubMed ID: 17502229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality among urban drug users and the impact of highly active antiretroviral therapy.
    Celentano DD
    Clin Infect Dis; 2005 Sep; 41(6):873-4. PubMed ID: 16107988
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoepidemiological approach to the predisposing factors for highly active antiretroviral therapy failure in an HIV-positive cohort from Cordoba City (Argentina) 1995-2005.
    Soria EA; Cadile II; Allende LR; Kremer LE
    Int J STD AIDS; 2008 May; 19(5):335-8. PubMed ID: 18482965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Start anti-HIV treatment early, in adults and infants.
    Laurence J
    AIDS Read; 2009 Jan; 19(1):6-7, 17. PubMed ID: 19209449
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of depression in predicting antiretroviral adherence in Ugandan parents and their children initiating HAART in the MTCT-plus family treatment model: commentary on Jayne Byakika-Tusiime et al. 2009.
    Nakimuli-Mpungu E; Musisi S
    AIDS Behav; 2009 Oct; 13(5):969-72. PubMed ID: 19662522
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy.
    Hashimoto T; Nishio M; Sakai T; Fujimoto K; Sato N; Endo T; Koike T
    Clin Infect Dis; 2006 Jun; 42(11):1653-5. PubMed ID: 16652326
    [No Abstract]   [Full Text] [Related]  

  • 17. Adherence in antiretroviral therapy: a review of qualitative studies.
    Vervoort SC; Borleffs JC; Hoepelman AI; Grypdonck MH
    AIDS; 2007 Jan; 21(3):271-81. PubMed ID: 17255734
    [No Abstract]   [Full Text] [Related]  

  • 18. [Assessment of factors associated with patients' comprehension of treatment at the start of antiretroviral therapy].
    Braga Ceccato Md; Acurcio Fde A; Vallano A; Comini César C; Crosland Guimarães MD
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):7-13. PubMed ID: 19217997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
    Collini P; Schwab U; Sarfo S; Obeng-Baah J; Norman B; Chadwick D; Bibby D; Bedu-Addo G
    Clin Infect Dis; 2009 Apr; 48(7):988-91. PubMed ID: 19231976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
    Warszawski J; Tubiana R; Le Chenadec J; Blanche S; Teglas JP; Dollfus C; Faye A; Burgard M; Rouzioux C; Mandelbrot L;
    AIDS; 2008 Jan; 22(2):289-99. PubMed ID: 18097232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.